3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
36
Neoplasms
8
HER2-positive Breast Cancer
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Salivary Gland Neoplasms
2
Pathologic Complete Response
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
Liver Neoplasms
1
Hemangiosarcoma
1
Heart Failure
1
Interventions
entrectinib
2
atezolizumab
2
alectinib
2
venetoclax
1
pertuzumab
1
obinutuzumab
1
ibrutinib
1
etoposide phosphate
1
enzalutamide
1
cobimetinib
1
capmatinib
1
acalabrutinib
1
Vincristine
1
Vemurafenib
1
Trastuzumab
1
Specimen Handling
1
Rituximab
1
Radiotherapy
1
Prednisone
1
Positron-Emission Tomography
1
Nivolumab
1
Genetic Testing
1
Genetic Counseling
1
Follow-Up Studies
1
Etoposide
1
Doxorubicin
1
Cyclophosphamide
1
Chromatin Immunoprecipitation Sequencing
1
CA-4948
1
Biological Assay
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoproliferative Disorders
×
pertuzumab
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled